Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Impax Laboratories Inc (NASDAQ:IPXL)

Delayed Data
As of May 27
 +0.55 / +1.67%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Generic

Company Description

Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture and marketing of controlled-release and niche generics. It operates through two segments: Global Pharmaceuticals and Impax Pharmaceuticals. The Global Pharmaceuticals segment concentrates its efforts on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products. The Impax Pharmaceuticals segment focuses on the development of proprietary brand pharmaceutical products addressing central nervous system disorders. The company was founded on December 14, 1999 and is headquartered in Hayward, CA.

Contact Information

Impax Laboratories, Inc.
30831 Huntwood Avenue
Hayward California 94544-7003
P:(510) 240-6000
Investor Relations:
(215) 558-4526



Mutual fund holders45.32%
Other institutional45.06%
Individual stakeholders12.95%

Top Executives

George Frederick WilkinsonPresident, Chief Executive Officer & Director
Andrew SchaschlSenior Vice President-Global Operations
Bryan M. ReasonsChief Financial Officer & Senior Vice President
Jeffrey D. NornholdSenior Vice President-Technical Operations
Vishal K. GuptaCSO, Senior Vice President-Research & Development